With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
A combination vaccine developed to reduce the number of injections infants receive appears to provide less immunity than the vaccines administered individually, according to a study in the April 13 2005 issue of JAMA.
Jim P. Buttery and colleagues conducted a study to determine the immunogenicity and safety of a combination 9-valent pneumococcal-group C meningococcal conjugate candidate vaccine.
The researchers found:
Pnc9-MenC combination vaccine administered to infants at ages 2, 3, and 4 months demonstrated reduced group C meningococcal immunogenicity compared with MenC vaccine. The immunogenicity of concomitantly administered Hib and DTwP vaccines was also diminished. The Pnc9-MenC vaccine was safe and immunogenic for all contained pneumococcal serotypes.
Reference Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants: A Randomized Controlled Trial Jim P. Buttery; Anna Riddell; Jodie McVernon; Tracey Chantler; Laura Lane; Jane Bowen-Morris; Linda Diggle; Rhonwen Morris; Anthony Harnden; Steven Lockhart; Andrew J. Pollard; Keith Cartwright; E. Richard Moxon JAMA. 2005;293:1751-1758. Abstract
CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.